Verrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatological Association
Verrica Pharmaceuticals (NASDAQ: VRCA) announced that Dr. Gary Goldenberg has been elected as an active member of the American Dermatological Association (ADA), a prestigious recognition in dermatology.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Verrica Pharmaceuticals (NASDAQ: VRCA) announced that Dr. Gary Goldenberg has been elected as an active member of the American Dermatological Association (ADA), a prestigious recognition in dermatology. CEO Ted White praised Dr. Goldenberg for his contributions to the field. The ADA, founded in 1876, aims to improve dermatologic health care and is known for its influential role in dermatological education and research. Verrica focuses on developing treatments for skin diseases, including its late-stage candidate VP-102 for molluscum and warts, and has partnered with Lytix Biopharma to develop LTX-315 for dermatologic oncology.
Positive
- Dr. Gary Goldenberg's election to the ADA highlights Verrica's leadership in dermatology.
- Verrica's late-stage product VP-102 targets significant unmet medical needs.
Negative
- None.
Details
News Market Reaction – VRCA
The recorded move for VRCA in the trading session of this news was +2.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WEST CHESTER, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Gary Goldenberg, M.D., Verrica’s Chief Medical Officer, has been elected as an active member into the American Dermatological Association (ADA).
“We congratulate Gary on his well-deserved election into the ADA, one of the highest honors in dermatology,” said Ted White, Verrica’s President and Chief Executive Officer. “The ADA is the oldest and most prestigious dermatological society in the U.S. and its members are recognized leaders in dermatology research, education, organizational medicine, and patient care. Gary’s election into the ADA is a testament to his significant contributions to dermatology, and we are proud to have Gary on Verrica’s executive leadership team.”
Founded in 1876, the ADA was the first national dermatological society in the United States. The ADA’s mission is to recognize, discuss and develop solutions for problems in the area of dermatologic health care, research and education. In the execution of its enduring mission, the ADA has been responsible for the development of a number of dermatologic organizations including the American Academy of Dermatology, the Society for Investigative Dermatology, and the American Board of Dermatology. Membership in the ADA is achieved through nomination and election based on meritorious contributions to the field of medicine and dermatology.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
A. Brian Davis
Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com
William Windham
Solebury Trout
646.378.2946
wwindham@troutgroup.com
Media:
Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@troutgroup.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.